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ABSTRACT
Langerhans cells are dendritic cells that form the antigenic barrier of the human body.
They occur in nearly any tissue but are most prevalent in the skin, submucosa of the
bronchial tree, and other mucosae. Langerhans Cell Histiocytosis (LCH) develops
when these cells damage the tissues in which they reside through a combination of
inflammatory and monoclonal stimulation. The pulmonary variant of LCH involves the
lung parenchyma and creates many disturbances, including pulmonary hypertension
and obstructive and restrictive lung disease. Osseous involvement, in addition to the
pulmonary variant, presents with pulmonary masses and lytic bone lesions, which
sparks suspicion for malignancy. Early recognition of this rare pathology is important as
early treatment is clinically beneficial. The following explores a case of adult Pulmonary
Langerhans Cell Histiocytosis with osseous involvement.
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INTRODUCTION
Langerhans cells are dendritic cells that inhabit
almost any tissue but are predominant in the
skin and submucosal surfaces. They identify
antigens via toll-like receptors and present them
to T-lymphocytes within lymph nodes to induce a
cascade of immunologic responses.1,2 Langerhans
cells owe their name to German pathologist Paul
Langerhans, who initially postulated them to be
nerve endings.2 Derangement of these cells creates
damage in affected organs. This pathology was
previously known as various syndromes: eosinophilic
granuloma,3 Hand-Schuller-Christian disease,
Letterer Siwe disease,4-9 congenital self-healing
reticulohistiocytosis, Hashimoto-Pritzker disease4,
and Erdheim-Chester disease.10 In 1964, Lichtenstein
consolidated them into the syndrome Histiocytosis
X before the final change in nomenclature to
Langerhans Cell Histiocytosis (LCH).5
LCH has an incidence of 1-2 cases per/million,1,6-8,11,12
with males more effected (2-4:1).1,4,6,13 It is
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predominately a pediatric disease, seen in the first
three to four years of life,2-4,7,14 but can extend into
adolescence.5,9,13 Certain varieties of LCH can present
in the third to fourth decades of adulthood.1,13,15 One
of these “adult” variants is Pulmonary Langerhans Cell
Histiocytosis (PLCH), which has an incidence of 0.270.7 per 100,000 people16 and accounts for 10-14% of
all cases of LCH.4 More importantly, it accounts for
approximately 3-5% of adult lung disease,2 with over
90% of those affected being smokers.1-3,6,15 There is a
slight male predominance. This difference, along with
racial incidence, may be related to gender differences
in the smoking rate.14 Though patients are not directly
genetically predisposed to PLCH, familial cases are
noted.1,5 It is important to keep in mind that this
“adult” variant has occurred in children with extensive
passive smoke exposure.11
CASE PRESENTATION
A 36-year-old white female former smoker with a
ten pack per year history, who was previously lost

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 8 Issue 1

FIGURE 1: 1A: X-ray of R shoulder and lytic lesion of scapula (yellow circle). 1B: CT of mediastinum. Diffuse small modularity throughout both lungs (R>L), predominantly upper lobe.
1C: MRI of 12 x 10 mm intensely enhancing extra-axial lesion of the parietal bone.

to follow-up after a breast mass biopsy, presented
with a several-month complaint of atraumatic right
shoulder pain and arm weakness. Her exam revealed
limited passive and active ROM of the shoulder due
to pain, with tenderness noted anteriorly. Shoulder
radiography revealed a lytic lesion in the right
scapula, as well as multiple lung nodules (Figure
1a). A follow-up computed tomography (CT) scan
of the chest demonstrated “innumerable bilateral
pulmonary nodules concerning for metastatic
disease” (Figure 1b). Additionally, there were lytic
lesions in the ninth right rib and both the twelfth
thoracic and first lumbar vertebral bodies, suggestive
of an osseous focus of this “metastatic disease.”
The patient was referred to oncology for further
evaluation. Two weeks later, a Positron Emission
Tomography (PET) scan revealed hypermetabolic
lytic bone lesions in the proximal left humerus and
right scapula. There was no hypermetabolic activity
of the ninth rib, either vertebral lesion, or any other
areas, including the multiple lung nodules. A bone
biopsy of the left humeral lesion demonstrated
sheets of eosinophils and histiocytes, most with
MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

mono-lobulated, but some with multi-lobulated
nuclei (Figure 2). Neutrophils, lymphocytes, and
plasma cells were present, along with patchy
areas of necrosis. Staining demonstrated CD68,
S100, and CD1a (Figure 3). A follow-up MRI of the
brain revealed a 12 x 10 mm enhancing parietal
bone lesion without parenchymal lesions or other
abnormalities (Figure 1c). The patient underwent
a regimen of cytarabine (AraC), and PET scanning
revealed a positive response to treatment with only
minute areas of residual hypermetabolic activity.
The patient continues to report significant bone
pain, including headaches in the area of the parietal
lesion, as well as incapacitating fatigue. She is
receiving symptom and pain management and will
continue to follow up with oncology.
DISCUSSION
Pathophysiology
The pathophysiology of LCH is not well understood.
It is a dual process of inflammation and clonal
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FIGURE 2. Figure 2A top image depicts eosinophils (pink) admixed with the neoplastic LCH cells (purple). Evidence of
macrophage activation with hemophagocytosis is noted (arrows). (H&E stain at 200x magnification). Figure 2B left lower
image shows the “coffee-bean” nuclear appearance of the LCH cells (arrow). (H&E stain at 500x magnification with oil).
Figure 2C right lower image shows the delicate nuclear grooves in LCH cells (arrows). (H&E stain at 1000x magnification
with oil).

FIGURE 3: Top image shows the strong expression of CD1a in the neoplastic cells (arrows), characteristic of LCH cells. The
cells are also positive for S100 with paranuclear dot-like expression of CD68 (not pictured); CD1a immunohistochemical
stain; Top image 200x magnification. Bottom image is CD1a at 400x magnification.
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proliferation,15 as evidenced by cytokine and
inflammatory cell presence for the former7,8,16 and
immature myeloid dendritic cell production (many
with oncogenic mutations in BRAF V600E)1-4,8,10,15
from abnormal bone marrow for the latter.1,3,7 The
location of these cells upon alteration determines
the clinical picture.
The case-patient exhibits PLCH with osseous
involvement based on the above presentation.
In the lungs, Langerhans cells are essential in the
antigenic barrier of the submucosa and have potent
lymphostimulatory capacity.14 Cigarette smoke,
which is involved in 90-95% of cases,1,3,5,6,14,15 can
incite lymphocytic accumulation1,3 and inflammation
through cytokine induced1,3,7,14 macrophage
activation (Figure 4).3 This leads to parenchymal
fibrosis through remodeling, as 1-10 millimeter
ground-glass nodules with lucent centers appear
near bronchioles early in the disease. Later in
the disease, nodules regress and leave cysts in
the negative space. These cysts enlarge further
with the traction of the developing parenchymal
fibrosis, creating an irregularly shaped honeycomb
pattern.1,2,6 Furthermore, these changes occur within
the tissue around the arterial-venous vascular bed,
blurring the architecture and thickening the vascular
walls. Advanced pulmonary vascular thickening
leads to pulmonary hypertension and can eventually
affect cardiac function.1,2,15
Pulmonary Langerhans Histiocytosis
At the time of diagnosis, 25% of patients with PLCH
are asymptomatic.1,61,6 Presentation is insidious and
variable,2,14 with initial pulmonary or constitutional
symptoms preceding diagnosis by 6-12 months.1
Pulmonary symptoms are prevalent in two-thirds
of cases and include cough, dyspnea, exercise
intolerance, and pneumothorax, the latter of which
is the presenting symptom 10-30% of the time.1,14,15
Usually, there are no abnormal lung sounds,1,14,15
and hemoptysis is uncommon.1,2,15 Constitutional
symptoms can consist of weight loss, fatigue, and
night sweats in 10-20% of cases.1,15 Late symptoms
include both obstructive and restrictive lung
disease,15 right-sided heart failure, and pulmonary
hypertension.1,2
Initial assessment of PLCH is directed by the variable
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nature of the disease process. Work-up should
involve evaluation of disease extent7 and functional
restrictions, in addition to the diagnosis (Table 1).
Imaging of the pulmonary fields shows the abovementioned lesions that spare the bases of the lungs
early in the process and transform into a “tree-inbud” appearance when the cysts’ walls thicken.2,15
Since malignancy is primary in the differential, tissue
collection through biopsy via bronchoscopy and
bronchoalveolar lavage is common. Unfortunately,
this modality is poorly sensitive, providing a 10-50%
chance of diagnosis. Poor sensitivity is attributed
to this focal pathology’s uneven distribution and
accessibility.1,2,14,15 Also, later in the disease, the tissue
can appear “burnt out” by yielding only fibrotic tissue
to sample.2 Open lung biopsy guided by CT is more
definitive in its sampling but can further compromise
lung function, so it should be used with caution.1,4,15
If appropriate tissue is obtained, electron
microscopic evaluation of histological studies
showing Langerhans cells containing Birbeck’s
granules and immunochemical studies for
S-100, CD1a, and Langerin can better secure the
diagnosis.2,5,6,14 PET scans may show uptake early in
the process, potentially confusing the differentiation
from malignancy.2,15 Skeletal survey, panorex
radiographs, and laboratory evaluation revolve
around determining extra-pulmonary involvement.15
Pulmonary function tests (PFTs) are within normal
limits 10-20% of the time.1,15 Spirometry may reveal
an overall mixed pattern: restrictive with total lung
capacity less than 80% of predicted early in the
disease2,15 and obstructive from hyperinflation1,2,14
later on.15 A decrease in diffusion capacity of carbon
monoxide (DLCO) is demonstrative of a defect in
oxygen diffusion and seen in 80-90% of cases.1,2,14,15
Echocardiography is important to diagnose
pulmonary hypertension as a pulmonary artery
pressure greater than 35 mmHg carries increased
mortality.2,15
Extra-Pulmonary Involvement of Pulmonary Langerhans
Histiocytosis
PLCH is classified as single-system LCH (SS-LCH)
when confined to the lung and occurs in 20-55%
of cases.2,17 Extra-pulmonary involvement with
PLCH is possible, favoring bone3,13 and the posterior
pituitary.1,3,16 The skin,3,4,13 thymus,1 lymph nodes,1,4,13
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spleen,4,13 liver,1,4,13 thyroid,11,16 intestine,1,11 oral
mucosa,4 and central nervous system (CNS)4 have
also been reported. Not only do the symptoms
change depending on the system involved, but
extra-pulmonary involvement also alters the
classification to multi-system LCH (MS-LCH).1,4,6,15,16
With this change, prognosis is negatively affected by
high-risk organ involvement, for which bone marrow,
the spleen, liver, and CNS qualify.1,4,6,15,16 This patient
qualifies for MS-LCH due to osseous involvement of
the parietal region of the skull, scapula, vertebrae,
and ribs. When bone is involved, it appears as sharply
demarcated lytic lesions,3,13 favoring the skull (2629%), long tubular bones (11-12.4%), ribs (11.1-12%),
mandible (9%), and spine (7%).4-6,8,9,11,13 Thoracic
(54%) and lumbar (35%) vertebrae outpace cervical
(11%) in frequency.99 Onset of osseous involvement is
slow and may be either painless or painful.13 A biopsy
revealing CD207/CD1a+ histocytes, eosinophils, and
multinucleated cells13 is needed to distinguish LCH
from primary or metastatic malignancy,4,8 fibrous
dysplasia, and hyperostosis.13
Treatment of Both Lung and Bone
Early treatment initiation is key for potential success
as late cystic lesions tend to resist improvement.6
Smoking cessation is paramount in treating PLCH
as this removes an inflammatory instigator and
allows for potential regression.1-3,6,14,15 Any lower
lung disease should be aggressively treated with
steroids, beta-agonists, and oxygen. Influenza
and pneumonia vaccines (PCV-13 and PCV-23)
should be strongly encouraged. Symptomatic
drainage and pleurodesis of symptomatic, recurrent
pneumothorax are important15, and lung transplants
may be contemplated.3,15 Immune modulators, such
as glucocorticoids1-3,15 and cytotoxic agents, may
include methotrexate,1-3 Vinblastine,1,15 Cladribine,6,15
Cyclophosphamide,33 and Etoposide,33 can modify
the progression of the disease. Generally, cytotoxic
agents are reserved for MS-LCH with high risk or
critical organ involvement; however, they can be
used for SS-LCH with multiple or high-risk lesions,
allowing utilization of steroids for more focal
disease.1-3,11 These guidelines may be employed
differently depending upon the patient’s age.1,15,17
The risk of disease progression should determine
treatment of osseous lesions. Observation8,13 and
local treatment consisting of curettage, intra-lesional
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steroids, bracing, and radiation4,7,8,13 are reserved
for osseous SS-LCH.4,13 More aggressive categories
can require systemic treatments with immune
modulators or cytotoxic agents as above.4,7
Prognosis of PLCH
Patients with PLCH can experience a spontaneous
regression,8,9 especially if smoking cessation is
successful early,1,3,6,14,15 but there is a 40% recurrence
rate.11 Forty percent, however, will experience a
significant decrease in FEV1 and DLCO in the first
two years after diagnosis, and 10-20% eventually
develop progressive respiratory failure and cor
pulmonale.15 Survival rates approach 75% at five
years and between 50-64% at ten years.1,2 Median
survival is 12.5 years.2 Poor prognosis is associated
with complications, extremes of age, prolonged
symptoms and treatment, decreased lung function,
and multiorgan involvement.1,3,7,11-15,18
CONCLUSION
Adult patients with lytic bone lesions and multiple
lung masses usually signal advanced lung cancer
to most physicians and carry a poor prognosis.
Rarely is a form of LCH considered in adults due to
its pediatric etiology. Physicians should be familiar
with this variant to rapidly initiate treatment and
smoking cessation. Additional cases of LCH should
be reported to further our understanding of this
diverse pathology.
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